CL2014003566A1 - Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson. - Google Patents

Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.

Info

Publication number
CL2014003566A1
CL2014003566A1 CL2014003566A CL2014003566A CL2014003566A1 CL 2014003566 A1 CL2014003566 A1 CL 2014003566A1 CL 2014003566 A CL2014003566 A CL 2014003566A CL 2014003566 A CL2014003566 A CL 2014003566A CL 2014003566 A1 CL2014003566 A1 CL 2014003566A1
Authority
CL
Chile
Prior art keywords
amimo
pyrimidines
pyrrolo
disease
substituted
Prior art date
Application number
CL2014003566A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Robert Verhoest
Paul Galatsis
Matthew Merrill Hayward
Jaclyn Henderson
Bethany Lyn Kormos
Ravi G Kurumbail
Antonia Friederike Stepan
Travis T Wager
Lei Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003566(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CL2014003566A1 publication Critical patent/CL2014003566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2014003566A 2012-06-29 2014-12-29 Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson. CL2014003566A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666299P 2012-06-29 2012-06-29
US201361820828P 2013-05-08 2013-05-08

Publications (1)

Publication Number Publication Date
CL2014003566A1 true CL2014003566A1 (es) 2015-04-10

Family

ID=49029142

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003566A CL2014003566A1 (es) 2012-06-29 2014-12-29 Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.

Country Status (31)

Country Link
US (2) US9156845B2 (enExample)
EP (2) EP2867236B1 (enExample)
JP (3) JP6189948B2 (enExample)
KR (1) KR20150027267A (enExample)
CN (2) CN104395315B (enExample)
AP (1) AP3902A (enExample)
AR (1) AR091628A1 (enExample)
AU (1) AU2013282869B2 (enExample)
BR (1) BR112014032913A2 (enExample)
CA (1) CA2878054C (enExample)
CL (1) CL2014003566A1 (enExample)
CO (1) CO7160063A2 (enExample)
CR (1) CR20140566A (enExample)
DO (1) DOP2014000303A (enExample)
EA (1) EA025186B1 (enExample)
ES (1) ES2637245T3 (enExample)
GE (1) GEP201706620B (enExample)
GT (1) GT201400301A (enExample)
IL (1) IL236294A (enExample)
MD (1) MD20140130A2 (enExample)
MX (1) MX2014015769A (enExample)
NI (1) NI201400151A (enExample)
NZ (1) NZ702571A (enExample)
PE (1) PE20150153A1 (enExample)
PH (1) PH12014502886A1 (enExample)
SG (1) SG11201408044QA (enExample)
TN (1) TN2014000537A1 (enExample)
TW (1) TWI482774B (enExample)
UY (1) UY34883A (enExample)
WO (1) WO2014001973A1 (enExample)
ZA (1) ZA201409136B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
EP2867236B1 (en) * 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
US8963597B1 (en) * 2013-10-02 2015-02-24 Nanya Technology Corporation Cross-domain enablement method and electronic apparatus
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN105980388B (zh) * 2014-01-29 2018-01-16 葛兰素史密斯克莱知识产权发展有限公司 化合物
EP3099695B1 (en) * 2014-01-29 2020-04-08 GlaxoSmithKline Intellectual Property Development Limited Compounds
WO2015176010A1 (en) * 2014-05-15 2015-11-19 The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services Treatment or prevention of an intestinal disease or disorder
CN104086553B (zh) * 2014-06-13 2016-04-27 南京药石科技股份有限公司 一种制备7-溴咪唑并[2,1-f][1,2,4]三嗪-4-胺的方法
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
JP6421241B2 (ja) 2014-11-14 2018-11-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼ阻害剤としての６−アミノ−７−ビシクロ−７−デアザ−プリン誘導体
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
EP3527570A4 (en) 2016-10-14 2020-04-15 Jiangsu Hengrui Medicine Co., Ltd. FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF
US10799507B2 (en) * 2017-02-03 2020-10-13 Leo Pharma A/S 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors
CN106831790B (zh) * 2017-02-17 2019-07-26 四川大学华西医院 7H-吡咯并[2,3-d]嘧啶衍生物
WO2018155947A1 (ko) 2017-02-24 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR20190131981A (ko) * 2018-05-18 2019-11-27 재단법인 대구경북첨단의료산업진흥재단 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물
KR101990739B1 (ko) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
WO2020040591A1 (ko) * 2018-08-23 2020-02-27 재단법인 대구경북첨단의료산업진흥재단 Lrrk 키나아제 저해제를 유효성분으로 함유하는 피리미딘 유도체의 신규용도
KR101992059B1 (ko) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020167628A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
JP7617030B2 (ja) 2019-05-08 2025-01-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤
JP2022544174A (ja) 2019-08-08 2022-10-17 ビマラン バイオサイエンシーズ，インク． Ｊａｋ阻害剤
AU2020354629A1 (en) * 2019-09-25 2022-04-21 Vimalan Biosciences, Inc. JAK inhibitors
KR20230012464A (ko) * 2020-02-25 2023-01-26 브이아이비 브이지더블유 류신-풍부 반복 키나제 2 알로스테릭 조절제
CN111671757A (zh) * 2020-07-16 2020-09-18 福建医科大学附属协和医院 3-[4-（4-吗啉基）-7h-吡咯并[2,3-d]嘧啶-5-基]苯甲腈制药用途
AU2021363536A1 (en) * 2020-10-20 2023-02-23 F. Hoffmann-La Roche Ag Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
WO2022093685A1 (en) * 2020-10-26 2022-05-05 Neuron23, Inc. Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2
CA3217559A1 (en) * 2021-05-05 2022-11-10 Kamaluddin Abdur-Rashid Catalytic tryptamine processes and precursors
MX2024002886A (es) * 2021-09-07 2024-05-24 Ptc Therapeutics Inc Metodos para tratar enfermedades neurodegenerativas.
US20250051337A1 (en) * 2021-09-28 2025-02-13 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023073013A1 (en) 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
AR130483A1 (es) 2022-09-15 2024-12-11 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
WO2025019585A1 (en) * 2023-07-17 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Kinase inhibitors
KR102847381B1 (ko) * 2024-02-07 2025-08-19 노보렉스 주식회사 Lrrk2 단백질 키나제 도메인 억제제로서 신규한 화합물
WO2025170397A1 (ko) * 2024-02-07 2025-08-14 노보렉스 주식회사 Lrrk2 단백질 키나제 도메인 억제제로서 신규한 화합물

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
JP2890448B2 (ja) 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
CA2011504C (en) 1989-03-07 1998-06-02 Kenji Ohmori Imidazoquinolone derivatives
US5721356A (en) * 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5763597A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5795977A (en) 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
JPH03271289A (ja) 1990-03-16 1991-12-03 Nissan Chem Ind Ltd ピラゾロピリジン誘導体の製造法及びジヒドロピラゾロピリジン誘導体
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP3130342B2 (ja) 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
JP3271289B2 (ja) 1992-02-28 2002-04-02 スズキ株式会社 ４サイクルエンジンのバルブ駆動装置
ATE197051T1 (de) 1992-04-03 2000-11-15 Upjohn Co Pharmazeutisch wirksame bicyclisch heterocyclische amine
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
JPH05310700A (ja) 1992-05-12 1993-11-22 Sagami Chem Res Center 縮合ピリジン系メバロノラクトン中間体及びその製法
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
JPH0641114A (ja) 1992-05-25 1994-02-15 Nissan Chem Ind Ltd 新規メバロノラクトン類とその製法
JPH06116239A (ja) 1992-10-05 1994-04-26 Nissan Chem Ind Ltd ７−置換−３，５−ジヒドロキシヘプタ−６−イン酸類
BR9307264A (pt) 1992-10-16 1999-05-11 Nippon Soda Co Derivados de pirimidina herbicida e fungicida
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
CA2154681A1 (en) 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
JP3350739B2 (ja) 1993-06-10 2002-11-25 コニカ株式会社 黒白ハロゲン化銀写真感光材料の現像処理方法
CN1102644A (zh) 1993-11-11 1995-05-17 财团法人相模中央化学研究所 缩合吡啶型甲羟戊酸内酯中间体及其制备方法
JPH07281365A (ja) 1994-04-07 1995-10-27 Konica Corp 写真感光材料の処理方法
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JP3448724B2 (ja) 1995-11-29 2003-09-22 コニカ株式会社 ハロゲン化銀写真感光材料用現像剤及びその処理方法
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
ES2203793T3 (es) * 1996-03-15 2004-04-16 Novartis Ag N-7-heterociclil-pirrolo(2,3-d)pirimidinas y su empleo.
JPH10213887A (ja) 1996-11-26 1998-08-11 Konica Corp 黒白ハロゲン化銀写真感光材料の処理方法
IL129825A0 (en) * 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
EP0846981A1 (en) 1996-12-03 1998-06-10 Konica Corporation Method for processing black-and-white silver halide photographic light-sensitive material
JP3543249B2 (ja) 1996-12-18 2004-07-14 コニカミノルタホールディングス株式会社 黒白ハロゲン化銀写真感光材料の処理方法
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
JP4666762B2 (ja) * 1998-06-19 2011-04-06 ファイザー・プロダクツ・インク ピロロ［２．３−ｄ］ピリミジン化合物
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US6309811B2 (en) 1999-07-21 2001-10-30 Eastman Kodak Company Color photographic element containing nitrogen heterocycle derivative and inhibitor releasing coupler
EP3150633A1 (en) 2000-02-24 2017-04-05 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
AU2002239764B2 (en) 2000-11-03 2007-06-21 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
WO2002051837A2 (en) 2000-12-22 2002-07-04 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
EP1463742A4 (en) * 2001-06-21 2006-05-10 Ariad Pharma Inc NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
AU2002339230A1 (en) 2002-03-08 2003-09-22 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
MXPA05001688A (es) 2002-08-12 2005-04-19 Sugen Inc 3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10259382A1 (de) 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
SI1696920T1 (sl) 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
US20050153989A1 (en) * 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
JP2007519707A (ja) 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク ヒスタミン−３受容体モジュレーター
SI1735278T1 (sl) 2004-04-01 2010-05-31 Lilly Co Eli Agenti histamin h receptorja priprava in terapevtska uporaba
JP5019612B2 (ja) 2004-04-02 2012-09-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｒｏｃｋの阻害剤として有用なアザインドールおよび他のプロテインキナーゼ
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
JP4069159B2 (ja) 2004-05-25 2008-04-02 ファイザー・プロダクツ・インク テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ
EP1773880A4 (en) 2004-06-08 2009-09-09 Novartis Vaccines & Diagnostic ENV POLYPEPTIDE COMPLEXES AND METHOD FOR THEIR USE
MXPA06015237A (es) 2004-06-29 2007-12-10 Amgen Inc Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
AP2007003890A0 (en) 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US8029986B2 (en) 2004-10-21 2011-10-04 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
EP1968568A4 (en) 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
ATE431426T1 (de) 2006-03-14 2009-05-15 Cellzome Ag Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2
WO2007124096A2 (en) 2006-04-21 2007-11-01 The Trustees Of Columbia University In The City Of New York Lrrk2 regulaton of neuronal process morphology
GB0610317D0 (en) 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
CA2657980A1 (en) * 2006-06-20 2007-12-27 Novartis Ag Biomarkers for the progression of alzheimer's disease
AU2007332143B2 (en) 2006-12-11 2012-11-08 Bionomics Limited Chemical compounds and processes
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
BRPI0806473A2 (pt) 2007-01-22 2011-09-27 Pfizer Prod Inc sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo
WO2008091799A2 (en) 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
FR2912744B1 (fr) 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
GB0706709D0 (en) 2007-04-05 2007-05-16 Medical Res Council Methods
JP2010523712A (ja) * 2007-04-13 2010-07-15 スーパージェン， インコーポレイテッド 癌または過剰増殖の治療に有用なａｘｌキナーゼ阻害剤
WO2008139293A1 (en) 2007-05-11 2008-11-20 Pfizer Inc. Amino-heterocyclic compounds
CL2008001540A1 (es) 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2009000319A1 (de) 2007-06-22 2008-12-31 Schulz Hans M Handeingabegerät
WO2009005730A1 (en) 2007-06-27 2009-01-08 Cornell University Transgenic animal models of parkinson's disease
WO2009030270A1 (en) 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
EP2197877B1 (en) 2007-09-14 2013-05-15 Sanofi 3-methyl-2- ( (2s) -2- (4- (3-methyl-1, 2, 4-oxadiazol-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
ATE535241T1 (de) 2007-12-05 2011-12-15 Univ Mainz Johannes Gutenberg Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2276346B1 (en) 2008-04-30 2016-11-23 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
DE102008025751A1 (de) 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
FR2935712A1 (fr) 2008-09-05 2010-03-12 Ct Hospitalier Regional Univer Methode de detection de l'expression differentielle d'un ensemble de marqueurs moleculaires associee a la maladie de parkinson
GB2463656B (en) 2008-09-18 2010-10-13 Medical Res Council Substrate of LRRK2 and methods of assessing LRRK2 activity
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
US20100175140A1 (en) 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
JP5908728B2 (ja) 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
EP2210887A1 (en) 2009-01-14 2010-07-28 Isdin, S.A. Bis resorcinyl triazine derivatives as protecting agents against UV radiation
US20100273769A1 (en) 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease
WO2010093191A2 (en) 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
PE20120506A1 (es) * 2009-03-19 2012-05-14 Medical Res Council Technology Derivados de pirazolopiridina como inhibidores de quinasas
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
KR20100116765A (ko) 2009-04-23 2010-11-02 인제대학교 산학협력단 파킨슨병 치료제 스크리닝 방법
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CA2775753A1 (en) 2009-09-29 2011-04-07 Paula Louise Nichols Lrrk2 kinase inhibitors
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
BR112012010085B1 (pt) 2009-10-29 2020-02-04 Genosco composto, quantidade terapeuticamente eficaz de um composto, formulação farmacêutica
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
WO2011057204A2 (en) * 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
CA2986631C (en) 2009-12-21 2020-06-02 Samumed, Llc 1h-pyrazolo[3,4-.beta.]pyridines and thereapeutic uses thereof
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US8367349B2 (en) 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2
EP2563125A4 (en) 2010-04-27 2013-10-02 Merck Sharp & Dohme AZAINDOLE AS JANUSKINASE HEMMER
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
US8895581B2 (en) 2010-05-17 2014-11-25 Boehringer Ingelheim International Gmbh 1H-imidazo[4,5-c]quinolines
WO2011149827A1 (en) 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
US9303322B2 (en) 2010-05-24 2016-04-05 Integran Technologies Inc. Metallic articles with hydrophobic surfaces
JP5713367B2 (ja) 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
KR101208198B1 (ko) 2010-08-27 2012-12-04 인제대학교 산학협력단 Ｌｒｒｋ２ 인산화효소 억제 활성을 갖는 화합물을 유효성분으로 함유하는 파킨슨병 치료 또는 예방용 약학조성물
JP5781611B2 (ja) 2010-09-02 2015-09-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｒｒｋ２キナーゼ阻害剤としての２−（ベンジルオキシ）ベンズアミド類
CA2810708A1 (en) 2010-09-16 2012-03-22 Hutchison Medipharma Limited Fused heteroaryls and their uses
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JP5310700B2 (ja) 2010-10-27 2013-10-09 パナソニック株式会社 Ｌｅｄパッケージ製造システムおよびｌｅｄパッケージ製造システムにおける樹脂塗布方法
US9233977B2 (en) 2010-10-29 2016-01-12 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
HUE037844T2 (hu) 2010-11-10 2018-09-28 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
CA2818428A1 (en) 2010-11-30 2012-06-07 Genentech, Inc. Assays and biomarkers for lrrk2
US20130338106A1 (en) 2011-02-28 2013-12-19 John A. McCauley Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9493452B2 (en) 2011-03-24 2016-11-15 Southern Methodist University Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
GB201105137D0 (en) 2011-03-28 2011-05-11 Isis Innovation Therapeutic molecules for use in the suppression of Parkinson's disease
WO2012135631A1 (en) 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
CN103492389B (zh) 2011-04-21 2016-09-14 原真股份有限公司 用作激酶抑制剂的吡唑并[4,3-d]嘧啶
WO2012143143A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
WO2012159079A1 (en) 2011-05-18 2012-11-22 The Parkinson's Institute Assay to determine lrrk2 activity in parkinson's disease
JP6047556B2 (ja) 2011-05-23 2016-12-21 エラン ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｌｒｒｋ２キナーゼ活性の阻害剤
US20140205537A1 (en) 2011-06-24 2014-07-24 Zenobia Therapeutics, Inc. Lrrk2 inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
US9096609B2 (en) 2011-09-30 2015-08-04 Ipsen Pharma S.A.S. Macrocyclic LRRK2 kinase inhibitors
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
WO2013166276A1 (en) 2012-05-02 2013-11-07 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
WO2013164321A1 (en) 2012-05-03 2013-11-07 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP6116239B2 (ja) 2012-12-28 2017-04-19 キヤノン株式会社 被検体情報取得装置および被検体情報取得方法
JP6041114B2 (ja) 2013-03-21 2016-12-07 ▲華▼▲為▼▲終▼端有限公司 データ送信方法、基地局、及びユーザ装置
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EP3119347B1 (en) 2014-03-21 2023-06-07 Align Technology, Inc. Segmented orthodontic appliance with elastics

Also Published As

Publication number Publication date
CN104395315A (zh) 2015-03-04
IL236294A0 (en) 2015-02-26
MX2014015769A (es) 2015-04-10
JP2019073522A (ja) 2019-05-16
EP2867236A1 (en) 2015-05-06
AR091628A1 (es) 2015-02-18
UY34883A (es) 2014-01-31
JP6462795B2 (ja) 2019-01-30
PE20150153A1 (es) 2015-02-05
EP3255049A1 (en) 2017-12-13
PH12014502886B1 (en) 2015-02-23
AP2014008147A0 (en) 2014-12-31
BR112014032913A2 (pt) 2017-06-27
PH12014502886A1 (en) 2015-02-23
IL236294A (en) 2016-09-29
US9642855B2 (en) 2017-05-09
EP2867236B1 (en) 2017-06-14
US9156845B2 (en) 2015-10-13
JP2015522002A (ja) 2015-08-03
AU2013282869B2 (en) 2015-12-24
US20150366874A1 (en) 2015-12-24
TWI482774B (zh) 2015-05-01
TW201414736A (zh) 2014-04-16
EA201492125A1 (ru) 2015-06-30
GEP201706620B (en) 2017-02-10
JP2017226684A (ja) 2017-12-28
SG11201408044QA (en) 2015-01-29
CO7160063A2 (es) 2015-01-15
KR20150027267A (ko) 2015-03-11
AP3902A (en) 2016-11-17
WO2014001973A1 (en) 2014-01-03
US20140005183A1 (en) 2014-01-02
JP6189948B2 (ja) 2017-08-30
HK1204619A1 (en) 2015-11-27
CR20140566A (es) 2015-01-09
CN104395315B (zh) 2016-08-17
NI201400151A (es) 2015-06-05
ES2637245T3 (es) 2017-10-11
AU2013282869A1 (en) 2015-01-15
CN105732639A (zh) 2016-07-06
NZ702571A (en) 2017-02-24
CA2878054C (en) 2018-09-11
ZA201409136B (en) 2016-08-31
CA2878054A1 (en) 2014-01-03
GT201400301A (es) 2015-06-02
MD20140130A2 (ro) 2015-04-30
DOP2014000303A (es) 2015-03-15
TN2014000537A1 (fr) 2016-03-30
EA025186B1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
CL2013001604A1 (es) Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
LT3333161T (lt) 2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
BR112013025792A2 (pt) Inibidores de quinase relacionada à pirrolo[2,3-d] pirimidina tropomisina
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112014000653A2 (pt) inibidores de tirosina quinase de bruton
BR112013029620A2 (pt) inibidores de tirosina quinase de bruton
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014028395A2 (pt) derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
EP2858500A4 (en) BRUTON TYROSINE KINASE HEMMER
CL2014000289A1 (es) Compuestos derivados de 3,4-dihidro-1h-[1,8]naftiridonas sustituidas, inhibidores de la actividad de la enzima fabl; proceso para preparar dichos compuestos; composicion farmaceutica que los comprende; y proceso para preparar esta composicion farmaceutica.
BR112015005361A2 (pt) inibidores de tirosina quinase de bruton
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
EP2833886A4 (en) SUBSTITUTED QUINOLINES AS INHIBITORS OF BRUTON TYROSINE KINASES
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.